Profil Institute Presents Diabetes, Obesity and NASH Research Study Results at the European Association for the Study of Diabetes Annual Meeting

Profil Institute Presents Diabetes, Obesity and NASH Research Study Results at the European Association for the Study of Diabetes Annual Meeting

SAN DIEGO, September 10, 2015 – Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, and sponsors will present prominent study results at next week’s European Association for the Study of Diabetes (EASD) 51th Annual Meeting, September 14-18 in Stockholm, Sweden.

Poster presentations co-authored by Profil Institute scientists include:
Significant effects of HM11260C on body weight over 20 weeks in obese subjects without diabetes: a randomized, double-blind, placebo controlled study || Abstract #643
Tuesday, September 15, 2015, 13:45 – 14:45, Poster Hall
PS 050 GLP-1 based therapies for obesity

A single dose study in healthy subjects demonstrating pharmacokinetic and pharmacodynamic equivalence between MK-1293 and EU- and US-approved innovator insulin glargine || Abstract #966
Tuesday, September 15, 2015, 12:30 – 13:30, Poster Hall
PS 091 Basal insulin therapy

Superagonistic mechanism of increased glucodynamic and weight loss effects of LAPSCA-Exendin-4 (efpenglenatide) || Abstract #788
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

Potent weight loss mechanism and effect on NASH of the novel long-acting GLP-1/Glucagon dual receptor agonist (HM12525A) || Abstract #790
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

The ultra-long acting LAPSGLP/GCG dual agonist, HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study || Abstract #791
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

LAPSExendin-4 (HM11260C) enhances insulin secretion and beta cell responsiveness in subjects with type 2 diabetes || Abstract #792
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

Dose-response improvements in glycaemic control and body weight reduction with HM11260C, a once weekly GLP-1 receptor agonist with liraglutide as reference, in type 2 diabetes || Abstract #793
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 069 GLP-1 receptor agonists: approaching approvability

A novel once weekly combination of long-acting GLP-1R agonist and insulin analog (HM14220) offers favorable PK/PD and mitogenic properties || Abstract #935
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall
PS 087 New and emerging insulin therapies

Oral presentations include:
BIOD-531 demonstrates superior prandial glucose control, post-meal dosing flexibility, and less insulin “stacking” compared to marketed prandial/basal insulins || Abstract #6
Tuesday, September 15, 2015, 12:00 – 12:15, Hellerström Hall
OP 01 Insulin analogues: Is newer always better?

Unique profile of the weekly insulin HM12470: Very slow onset of action, rapid off-rate similar to insulin, and absence of insulin receptor downregulation || Abstract #41
Tuesday, September 15, 2015, 16:00 – 16:15, Hellerström Hall
OP 07 A glimpse at future diabetes therapy

Once a month treatment with HM11260C improves glycaemic control in type 2 diabetes mellitus: interim data from a 16-week study || Abstract #113
Wednesday, September 16, 2015, 17:00 – 17:15, Hellerström Hall
OP 19 incretin-based therapy: novel agents, new indications

Poster session chaired by Profil Institute’s Dr. Marcus Hompesch:
PS 051 Obesity: emerging concepts in aetiopathogenesis
Wednesday, September 16, 2015, 12:30 – 13:30, Poster Hall

About Profil Institute for Clinical Research, Inc.
Profil Institute is an early engagement clinical research organization (CRO) exclusively focused on metabolic diseases, including diabetes, obesity and NAFLD/NASH. The company is recognized globally for its scientific expertise, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. Profil Institute provides a full scope of CRO services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.

Profil Institute is also widely recognized as an innovator of methodologies, including its Automated Glucose Clamp technology, and for driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners. For more information, visit www.profilinstitute.com.

For further information, please contact:
Abby Devine
Profil Institute for Clinical Research, Inc.
Corporate Communications
abby.devine@profilinstitute.com
+1 (858) 663-6148